Kathleen King’s Post

In 2022, the pharmaceutical manufacturer Biogen paid $900 million to settle a lawsuit for paying kickbacks to persuade doctors to prescribe its drugs for multiple sclerosis. Biogen did not admit wrongdoing, but the suit asserted that the company used consulting fees and honorariums for participation in speakers programs and advisory boards to induce the doctors to prescribe the drugs. Though this lawsuit is another example of a well known industry strategy, the extent of the program was dramatic. In BMJ, Joseph Ross, Reshma Ramachandran, and I give details on the Biogen case and draw lessons from this case and several others for doctors' engagement with industry through consulting, speakers programs, and advisory board service. You can read more here (please DM me if stuck behind the paywall): https://lnkd.in/ehb_pWvy

ICCR Senior Director for Health Equity, Meg Jones-Monteiro, discusses how patent abuse not only harms patients, but also reflects short-term thinking— something investors do not want to see from the pharmaceutical industry. Read her full interview in I-MAK’s new partnership with Politico. https://politi.co/4iHUX3G

A carrier finally acting in the best interest of their consumers. We've been doing this on the self insured side for years. If there is no competition, there are no price pressures. This approach will gain momentum and put additional pressure on PBMs to find a way to either get the pharmaceutical companies to reduce R&D costs or for both entities to reduce profits. However, don't expect the PBMs to go down without a fight. They have some of the best lobbyists in the world. https://lnkd.in/eGMd33fh

Each year, industry observers compile lists of top drugs expected to lose exclusivity, based on factors such as U.S. sales from the previous year. In 2024, this list includes blockbusters from Bristol Myers Squibb and Biogen, alongside renowned medicines from Novo Nordisk, Astellas, and Novartis. Additionally, companies like PTC Therapeutics, Organon, and Supernus are bracing for significant potential losses of exclusivity. Read more: https://lnkd.in/drXVJxbt The Hatch-Waxman/ANDA litigation space is highly competitive, with many law firms struggling to stand out and pharmaceutical companies searching for the best counsel. The Patexia's ANDA Intelligence Report offers a solution by evaluating and ranking all stakeholders in Hatch-Waxman/ANDA cases, including attorneys, local counsel, law firms, judges, plaintiffs, and defendants, accompanied by an Excel file with detailed statistics for each player. The report also includes information on lateral moves that have taken place in the last year. Get your own copy here: https://lnkd.in/dRUUyB_x #patent #fda #drugs #pharma #Pharmaceutical #exclusivity #anda #hatchwaxman

a very detailed discussion of the pricing of drugs and why Americans pay exorbitant prices for common pharmaceutical drugs. there are dozens of countries where citizens and residents pay substantially less for the same name brand as well as generic label pharmaceutical drugs. and no, it isn't about research costs. enjoy the read. https://lnkd.in/dERQ_cRD

Big BioPharma Appears to Be Unfazed by IRA Drug Price Negotiations Despite their initial kicking and screaming, drugmakers seem confident the Inflation Reduction Act’s Medicare Drug Price Negotiation Program will not greatly impact their bottom lines. The second-quarter 2024 biopharma earnings season is upon us. Johnson & Johnson and Novartis kicked off the parade of Q2 financial results last week, and this week AbbVie, AstraZeneca, Roche and Sanofi joined the litany of announcements as well as Bristol Myers Squibb. So far, like most earnings seasons, it has been a ho-hum affair, with companies beating Wall Street expectations on strong drug sales and raising their outlooks for the rest of the year. Everything seems to be coming up roses for Big Pharma. https://lnkd.in/gCUf8zh5 #aspenalert #biotech #bioprocess

Collaboration has always been integral to creating advanced, innovative, and comprehensive medical treatments and health systems, which is why it's great to see China's stride in drug research for global healthcare. While these collaboration opportunities are promising, pharmaceutical and healthcare companies also need to be mindful of challenges, like pricing and procurement reluctance - both of which highlight the complexity of the pharmaceutical landscape. These insights inspire collective efforts to drive healthcare innovation forward, promising boundless possibilities for the future. #HealthcareInnovation #DrugResearch #MedicalAdvancement

This is a must-read for anyone in the healthcare and pharmaceutical sectors! David Schweihs details the impact #DSCSA serialization will have on the crucial issue of drug shortages – and some opportunities for solutions. How do you think DSCSA will shape the future of patient care? Share your thoughts in the comments! #Healthcare #Pharma

This insightful article challenges the common justification for high US drug prices—that they fund R&D. 💊 It reveals that the premium charged in the US far exceeds what companies spend on global research. 📊 This discrepancy underscores the need for pricing reforms in the pharmaceutical industry. 🌍 A must-read for anyone interested in healthcare policy and drug pricing! 🏥 #Pharmaceuticals #HealthcarePolicy #DrugPricing #Innovation #R&D https://lnkd.in/eeSFrM7a

Trinity's latest blog focuses on two high impact policies in Canada, (i) the transformation of the former “Canadian Agency for Drugs and Technology in Health” (CADTH) into the new “Canadian Drug Agency” (CDA)", and (ii) CADTH's time-limited reimbursement recommendation pathway for innovative drugs, albeit with evidence uncertainties, which would also be eligible for the independent pan-Canadian Pharmaceutical Alliance (pCPA) Temporary Access Process, as announced last Friday. These policies present their own opportunities and challenges that pharmaceutical manufacturers will have to consider to optimize the pricing & market access potential for their assets in this market. Read the blog to learn more: https://bit.ly/43Qj614